AngioDynamics, Inc. (NASDAQ:ANGO) Stock Has Consensus Price Target of $19.00

Key Points

• Analysts have a Moderate Buy consensus on AngioDynamics, with five firms issuing ratings and an average 12-month price target of $19.00 versus the stock’s reported $11.05 price.
• AngioDynamics exceeded quarterly expectations, reporting an adjusted loss of $0.04 per share versus the expected $0.11 loss, while revenue of $80.92 million slightly topped estimates.
• Institutional investors own 89.43% of the company, with several funds recently initiating or increasing positions; however, the company remains unprofitable, with negative margins and projected full-year EPS of approximately -$0.25.

Shares of AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

ANGO has been the subject of several recent analyst reports. HC Wainwright cut their price objective on shares of AngioDynamics from $19.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday. Wall Street Zen lowered shares of AngioDynamics from a "buy" rating to a "hold" rating in a report on Saturday, October 10th. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 target price on shares of AngioDynamics in a research report on Friday, October 9th. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Zacks Research raised shares of AngioDynamics from a "strong sell" rating to a "hold" rating in a report on Monday, October 5th.

AngioDynamics Stock Up 1.4%

NASDAQ ANGO opened at $11.05 on Thursday. The company has a market capitalization of $464.65 million, a P/E ratio of -14.17 and a beta of 0.30. The firm has a 50-day moving average price of $15.08 and a two-hundred day moving average price of $13.12. AngioDynamics has a 12-month low of $9.39 and a 12-month high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The firm had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Equities analysts expect that AngioDynamics will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the business's stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently modified their holdings of ANGO. Canada Pension Plan Investment Board acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $428,000. Western Standard LLC bought a new stake in shares of AngioDynamics during the 2nd quarter valued at approximately $5,037,000. Bank of America Corp DE increased its position in AngioDynamics by 262.7% during the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier's stock worth $5,726,000 after purchasing an additional 364,763 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in AngioDynamics during the 2nd quarter worth approximately $1,619,000. Finally, Paradigm Capital Management Inc. NY acquired a new position in AngioDynamics during the 2nd quarter worth approximately $8,732,000. Institutional investors and hedge funds own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company's portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.